ALNY Alnylam Pharmaceuticals Inc
$255.96
Alnylam Pharmaceuticals Inc (ALNY) is expected to report earnings on November 2, 2026, before the market open. The consensus earnings estimate is $1.68 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +13.8% since its last earnings release on July 30, 2026.
Alnylam Pharmaceuticals Missed Consensus Estimates
Thursday, July 30, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 8:00 AM ET
Earnings Whisper
-
vs $1.68
Rev est $1.45B
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$231.92
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.
Sector
Healthcare
Industry
Biotechnology
Held By 12 ETFs, by dollar flow
- QQQ Invesco QQQ Trust
- QQQ Invesco QQQ Trust
- XT iShares Exponential Technologies ETF
- XT iShares Exponential Technologies ETF
- IYH iShares U.S. Healthcare ETF
- IYH iShares U.S. Healthcare ETF
- QQQJ Invesco NASDAQ Next Gen 100 ETF
- QQQJ Invesco NASDAQ Next Gen 100 ETF
- BMED iShares Health Innovation Active ETF
- BMED iShares Health Innovation Active ETF
- BBH VanEck Biotech ETF
- BBH VanEck Biotech ETF
Charts powered in part by Lightweight Charts™ by TradingView.